Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in TauP301L-BiFC mice

참고문헌 (89)

1. Kolarova, M., "Structure and pathology of tau protein in Alzheimer disease", Int. J. Alzheimers Dis, 2012, pp.731526~ (2012)
2. Kontaxi, C., "Lysine-directed post-translational modifications of tau protein in Alzheimer’s disease and related Tauopathies", Front. Mol. Biosci, 4, pp.56~ (2017)
3. Kadavath, H., "Tau stabilizes microtubules by binding at the interface between tubulin heterodimers", Proc. Natl Acad. Sci. USA, 112, pp.7501~7506 (2015)
4. Paglini, G., "Tau protein function in axonal formation", Neurochem. Res, 25, pp.37~42 (2000)
5. Stoothoff, W. H., "Tau phosphorylation: physiological and pathological consequences", Biochim. Biophys. Acta, 1739, pp.280~297 (2005)
6. Martin, L., "Post-translational modifications of tau protein : implications for Alzheimer’s disease", Neurochem. Int, 58, pp.458~471 (2011)
7. Chesser, A., "Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease", Front. Neurol, 4, pp.122~ (2013)
8. Serrano-Pozo, A., "Neuropathological alterations in Alzheimer disease", Cold Spring Harb. Perspect. Med, 1, pp.a006189~ (2011)
9. Lee, V. M., "Neurodegenerative tauopathies", Annu. Rev. Neurosci, 24, pp.1121~1159 (2001)
10. Himmelstein, D. S., "Tau as a therapeutic target in neurodegenerative disease", Pharmacol. Ther, 136, pp.8~22 (2012)
11. Shafiei, S. S, "Tau oligomers:cytotoxicity, propagation, and mitochondrial damage", Front. Aging Neurosci, 9, pp.83~ (2017)
12. Lasagna-Reeves, C. A., "Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice", Mol. Neurodegener, 6, pp.39~ (2011)
13. Kaniyappan, S., "Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability", Alzheimers Dement, 13, pp.1270~1291 (2017)
14. Maeda, S., "Granular tau oligomers as intermediates of tau filaments", Biochem, 46, pp.3856~3861 (2007)
15. Maeda, S., "Increased levels of granular tau oligomers : an early sign of brain aging and Alzheimer’s disease", Neurosci. Res, 54, pp.197~201 (2006)
16. Berger, Z., "Accumulation of pathological tau species and memory loss in a conditional model of tauopathy", J. Neurosci. Res, 27, pp.3650~3662 (2007)
17. Clavaguera, F., "Transmission and spreading of tauopathy in transgenic mouse brain", Nat. Cell Biol, 11, pp.909~913 (2009)
18. Frost, B., "Propagation of tau misfolding from the outside to the inside of a cell", J. Biol. Chem, 284, pp.12845~12852 (2009)
19. Kim, D., "Identification of disulfide cross-linked tau dimer responsible for tau propagation", Sci. Rep, 5, pp.15231~ (2015)
20. Haque, M., "Intracellular tau modifications and cell-based sensors for monitoring tau aggregation. Protein Purification:Principles and Trends", iConcept (2016)
21. Wischik, C. M., "O3-04–07 : Tau aggregation inhibitor(TAI)therapy with rember™ arrests disease progression in mild and moderate Alzheimer’s disease over 50 weeks", Alzheimers Dement, 4, pp.T167~ (2008)
22. Akoury, E., "Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation", Angew. Chem. Int. Ed. Engl, 52, pp.3511~3515 (2013)
23. Crowe, A., "Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation", J. Biol. Chem, 288, pp.11024~11037 (2013)
24. Walker, S., "Using intramolecular disulfide bonds in tau protein to deduce structural features of aggregation-resistant conformations", J. Biol. Chem, 287, pp.9591~9600 (2012)
25. Soeda, Y., "Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers : A plausible key to understanding failure of a clinical trial for Alzheimer’s disease", J. Alzheimers Dis, 68, pp.1677~1686 (2019)
26. Wilcock, G. K., "Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate)(LMTM)monotherapy for treatment of mild Alzheimer’s disease : Cohort analysis as modified primary outcome in a phase III clinical trial", J. Alzheimers Dis, 61, pp.435~457 (2018)
27. Gauthier, S., "Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease : a randomised, controlled, double-blind, parallel-arm, phase 3 trial", Lancet, 388, pp.2873~2884 (2016)
28. Biernat, J., "Phosphorylation of Ser262 strongly reduces binding of tau to microtubules : distinction between PHFlike immunoreactivity and microtubule binding", Neuron, 11, pp.153~163 (1993)
29. Lindwall, G., "Phosphorylation affects the ability of tau protein to promote microtubule assembly", J. Biol. Chem, 259, pp.5301~5305 (1984)
30. min, S. -W., "Acetylation of tau inhibits its degradation and contributes to tauopathy", Neuron, 67, pp.953~966 (2010)
31. Reynolds, M. R., "Site-specific nitration and oxidative dityrosine bridging of the τ protein by peroxynitrite: implications for Alzheimer’s disease", Biochem, 44, pp.1690~1700 (2005)
32. Tak, H., "Bimolecular fluorescence complementation; lighting-up tau-tau interaction in living cells", PLoS One, 8, pp.e81682~ (2013)
33. Shin, S., "Visualization of soluble tau oligomers in TauP301L-BiFC transgenic mice demonstrates the progression of tauopathy", Prog. Neurobiol, 187, pp.101782~ (2020)
34. Jeong, H., "Pan-HDAC inhibitors promote tau aggregation by increasing the level of acetylated tau", Int. J. Mol. Sci, 20, pp.4283~ (2019)
35. Lim, S., "Monitoring of intracellular tau aggregation regulated by OGA", OGT inhibitors, 2015, pp.16, 20212~20224
36. Choi, W. H., "Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation", Nat. Commun, 7, pp.1~12 (2016)
37. Sandell, E. -P., "Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure", J. Cardiovasc. Pharmacol, 26, pp.57~62 (1995)
38. Haque, M. M., "Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking", Amyloid, 21, pp.185~190 (2014)
39. Kim, S., "Functional interaction of neuronal Cav1. 3 L-type calcium channel with ryanodine receptor type 2 in the rat hippocampus", J. Biol. Chem, 282, pp.32877~32889 (2007)
40. Er, J. C., "NeuO : a fluorescent chemical probe for live neuron labeling", Angew. Chem. Int. Ed. Engl, 54, pp.2442~2446 (2015)
41. Leger, M., "Object recognition test in mice", Nat. Protoc, 8, pp.2531~2537 (2013)
42. King, D. L., "Behavioral characterization of the Tg2576transgenic model of Alzheimer’s disease through 19 months", Physiol. Behav, 75, pp.627~642 (2002)
43. Hsiao, K. K., "Age-related CNS disorder and early death in transgenic FVB", N mice overexpressing Alzheimer amyloid precursor proteins, 1995, pp.15, 1203~1218
44. Van der Poel, A., "Ethological study of the behaviour of the albino rat in a passiveavoidance test", Acta Physiol. Pharmacol. Neerl, 14, pp.503~ (1967)
45. Wang, H. -H., "Forskolin induces hyperphosphorylation of tau accompanied by cell cycle reactivation in primary hippocampal neurons", Mol. Neurobiol, 55, pp.696~706 (2018)
46. Yan, K., "The cyclic AMP signaling pathway : exploring targets for successful drug discovery", Mol. Med. Rep, 13, pp.3715~3723 (2016)
47. Yamada, K., "Analysis of in vivo turnover of tau in a mouse model of tauopathy", Mol. Neurodegener, 10, pp.1~9 (2015)
48. Sahara, N., "Assembly of two distinct dimers and higher-order oligomers from full-length tau", Eur. J. Neurosci. Res, 25, pp.3020~3029 (2007)
49. Patterson, K. R., "Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease", J. Biol. Chem, 286, pp.23063~23076 (2011)
50. Lasagna-Reeves, C. A., "Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau", Sci. Rep, 2, pp.1~7 (2012)
51. Lasagna-Reeves, C. A., "Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease", FASEB J, 26, pp.1946~ (2012)
52. Zhou, Y., "Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer’s disease", Front. Aging Neurosci, 10, pp.27~ (2018)
53. Taniguchi, S., "Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins", J. Biol. Chem, 280, pp.7614~7623 (2005)
54. Abskharon, R., "Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer’s disease", J. Biol. Chem, 295, pp.10662~10676 (2020)
55. Jackson, P. A., "Covalent modifiers : a chemical perspective on the reactivity of α, β-unsaturated carbonyls with thiols via hetero-Michael addition reactions", J. Med. Chem, 60, pp.839~885 (2017)
56. Antila, S., "Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators", Eur. J. Pharm. Sci, 23, pp.213~222 (2004)
57. Takahashi, R., "Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium", J. Cardiovasc. Pharmacol, 36, pp.118~125 (2000)
58. Dolan, P. J., "The role of tau kinases in Alzheimer’s disease", Curr. Opin. Drug Discov. Dev, 13, pp.595~ (2010)
59. Haikala, H., "Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan", J. Mol. Cell. Cardiol, 27, pp.1859~1866 (1995)
60. Pollesello, P., "Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study", J. Biol. Chem, 269, pp.28584~28590 (1994)
61. Yildiz, O., "Vasodilating mechanisms of levosimendan : involvement of K+ channels", J. Pharmacol. Sci, 104, pp.1~5 (2007)
62. Miki, T., "ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis", Nat. Neurosci, 4, pp.507~512 (2001)
63. Roehl, A. B., "Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury", BMC Neurol, 10, pp.97~ (2010)
64. Roehl, A. B., "The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia", hypoxia, 2012, pp.12, 1~10
65. Levijoki, J., "Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats", Eur. J. Pharmacol, 750, pp.132~140 (2015)
66. Kivikko, M., "Oral levosimendan increases cerebral blood flow velocities in patients with a history of stroke or transient ischemic attack : a pilot safety study", Curr. Ther. Res, 77, pp.46~51 (2015)
67. Rababa’h, A. M., "Levosimendan prevents memory impairment induced by diabetes in rats : role of oxidative stress", Curr. Alzheimer Res, 16, pp.1300~1308 (2019)
68. Chen, X., "Oxidative stress in neurodegenerative diseases", Neural Regen. Res, 7, pp.376~ (2012)
69. Haque, M. M., "Crosstalk between oxidative stress and tauopathy", Int. J. Mol. Sci, 20, pp.1959~ (2019)
70. Justin, B. N., "Heart disease as a risk factor for dementia", Clin. Epidemiol, 5, pp.135~ (2013)
71. de La Torre, J. C., "Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia", Cardiovasc. Psychiatry. Neurol, 2012, pp.367516~ (2012)
72. Park, S. H., "Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation", Biochem. Biophys. Res. Commun, 408, pp.602~608 (2011)
73. Maki, T., "Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-Amyloid", Ann. Clin. Transl. Neurol, 1, pp.519~533 (2014)
74. Pushpakom, S., "Drug repurposing : progress, challenges and recommendations", Nat. Rev. Drug Discov, 18, pp.41~58 (2019)
75. Ehrlich, P., "Ueber die wirkung des methylenblau bei malaria", Berl. Klin. Wochenschr, 28, pp.953~956 (1891)
76. Ginimuge, P. R., "Methylene blue : revisited", J. Anaesthesiol. Clin. Pharmacol, 26, pp.517~ (2010)
77. Boylston, M., "Methemoglobinemia : a case study", Crit. Care Nurse, 22, pp.50~55 (2002)
78. Ramsay, R., "Methylene blue and serotonin toxicity : inhibition of monoamine oxidase A(MAO A)confirms a theoretical prediction", Br. J. Pharm, 152, pp.946~951 (2007)
79. Lomniczi, A., "Methylene blue inhibits the increase of inducible nitric oxide synthase activity induced by stress and lipopolysaccharide in the medial basal hypothalamus of rats", Neuroimmunomodulation, 8, pp.122~127 (2000)
80. Farina, J. A., "Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. A medical hypothesis", Med. Sci. Monit, 18, pp.HY13~ (2012)
81. Wegener, G., "Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo", Br. J. Pharm, 130, pp.575~580 (2000)
82. Paya, D., "Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats", J. Cardiovasc. Pharmacol, 21, pp.926~930 (1993)
83. Oz, M., "Cellular and molecular actions of methylene blue in the nervous system", Med. Res. Rev, 31, pp.93~117 (2011)
84. Chen, C., "Methylene blue offers neuroprotection after intracerebral hemorrhage in rats through the PI3K", Akt, J. Cell. Physiol, pp.2019, 234[DOI]
85. Sun, W., "Attenuation of synaptic toxicity and MARK4", PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer’s disease treatment, 2016, pp.6, 34784~
86. Medina, D. X., "Methylene blue reduces Aβ levels and rescues early cognitive deficit by increasing proteasome activity", Brain Pathol, 21, pp.140~149 (2011)
87. Congdon, E. E., "Methylthioninium chloride(methylene blue)induces autophagy and attenuates tauopathy in vitro and in vivo", Autophagy, 8, pp.609~622 (2012)
88. Engmann, O., "Crosstalk between Cdk5 and GSK3β : implications for Alzheimer’s disease", Front. Mol. Neurosci, 2, pp.2~ (2009)
89. Aaron Ciechanover, "Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies", Experimental and Molecular Medicine, 47, pp.1~16 (2015), 생화학분자생물학회

관련 논문AI추천